September 17, 2013
1 min read

Aflibercept reduces subfoveal fluid in eyes with persistent exudative AMD

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Aflibercept yielded positive anatomic results in cases of exudative age-related macular degeneration that were resistant to ranibizumab or bevacizumab, according to a study.

“Visual acuity did not improve. Aflibercept may be beneficial anatomically in cases of exudative AMD treated with persistent fluid on ranibizumab and/or bevacizumab,” the study authors said.

The retrospective study included 353 eyes with exudative AMD and persistent fluid identified on spectral-domain optical coherence tomography (SD-OCT) despite regular treatment with ranibizumab 0.5 mg and/or bevacizumab 1.25 mg. Eyes received an average of 20 injections of ranibizumab or bevacizumab.

Treatment was switched to intravitreal aflibercept 2 mg (Eylea, Regeneron). Mean patient age at the time of the switch was 81 years.

After the switch, eyes were re-evaluated for a mean of 32 days. Aflibercept administration was monthly but treatment was extended to 6 to 8 weeks for 21 patients.

Twenty-eight eyes of 28 patients had persistent fluid after an average of 20 ranibizumab or bevacizumab injections. Anatomic improvement was seen in 25 of these 28 eyes at 1 month (89%); five eyes (18%) were dry after one aflibercept injection.

Central subfoveal thickness improved from 295 μm to 272 μm after one aflibercept injection; the improvement was statistically significant (P < .001).

No adverse events were reported, the authors said.

Disclosure: See the study for a full list of all authors’ relevant financial disclosures.